Lilak v. Astrazenca Pharmaceutical-US Inc., Corporation | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Lilak v. Astrazenca Pharmaceutical-US Inc., Corporation

Sort by

Viewing results 1‒4 of 4

Jonathan Guthrie
The fallacy behind the rise of passive fund management
...jonathan.guthrie@ft.com Letters in response to this column: Focus on the haystack — not on the needles / From Brendan P Geary, Washington, DC, US Active v passive: put more faith in market forces / From...
January 15, 2020
News in-depthCushman & Wakefield Inc
Cushman v the cleaner: the fight over non-competes
...The lawsuit is a stark example of the use of non-competes by large corporations, even against low-level hourly wage workers....
October 16, 2018
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
News in-depthThe Big Read
Quantum computing: the power to think outside the box
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
September 3, 2018
Work & Careers
The big defence challenge
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
April 20, 2005

Previous pagePage 1 of 1Next page